Long‐term survival and association of neoadjuvant chemotherapy with or without immunotherapy in resectable esophageal squamous cell carcinoma

Documenti analoghi

• Nomogram for predicting pathologic complete response to neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma
  di: Guihong Liu, et al.
  Pubblicazione: (2024)
• Evolution of genome and immunogenome in esophageal squamous cell carcinomas driven by neoadjuvant chemoradiotherapy
  di: Zelin Weng, et al.
  Pubblicazione: (2024)
• Neoadjuvant chemoimmunotherapy was associated with better short‐term survival of patients with locally advanced esophageal squamous cell carcinoma compared to neoadjuvant chemoradiotherapy
  di: Xiaofeng Duan, et al.
  Pubblicazione: (2024)
• Clinical prognostication and immunotherapy response prediction in esophageal squamous cell carcinoma using the DNA damage repair‐associated signature
  di: Pengpeng Zhang, et al.
  Pubblicazione: (2024)
• Polymeric Micellar Paclitaxel Plus Cisplatin Combined With Tislelizumab as the First‐Line Treatment of Advanced Unresectable Esophageal Squamous Cell Carcinoma: A Phase II Study
  di: Xiaoyou Li, et al.
  Pubblicazione: (2025)